Triplet Targeted Therapy May Signal a New Standard in Metastatic CRC
Anita T. Shaffer and Morgan Meisner, PhD
Published: Wednesday, Jul 17, 2019
Although therapies aimed at BRAF mutations have shown efficacy in several tumor types, these drugs have demonstrated limited success in studies involving patients with colorectal cancer (CRC).1 Now, investigators are combining BRAF inhibitors with other targeted therapies in an effort to establish a new chemotherapy-free standard in patients with metastatic disease.
... to read the full story